XENON XE 133 (xenon xe-133) by Lantheus Medical Imaging is radiopharmaceutical activity [moa]. First approved in 1974.
Drug data last refreshed 8h ago · AI intelligence enriched 1w ago
Xenon XE-133 is an inhaled radioactive gas diagnostic agent used for pulmonary ventilation imaging to assess lung function and blood flow. It works through radiopharmaceutical activity, allowing clinicians to visualize ventilation patterns and detect abnormalities in gas exchange. This agent has been a standard diagnostic tool in nuclear medicine for nearly 50 years.
As LOE approaches, brand teams are likely consolidating to focus on retention and market defense rather than growth initiatives.
Radiopharmaceutical Activity
Inhalation Diagnostic Agent
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on Xenon XE-133 offers limited career growth due to its mature lifecycle stage and approaching loss of exclusivity, with zero currently linked job openings. This role is best suited for professionals focused on operational excellence, compliance, and market defense rather than innovation or expansion.
Worked on XENON XE 133 at Lantheus Medical Imaging? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.